Business Wire

Beeline Russia and P.I. Works Expand Partnership Scope with Automated Radio Access Network Planning

20.4.2021 08:00:00 EEST | Business Wire | Press release

Share

Beeline, Russia’s established mobile operator, has partnered with P.I. Works on network planning project, aimed at streamlining the operator’s investment planning processes and revolutionizing customer experience. As a part of the project, P.I. Works SmartPlan, the cutting-edge automated and AI driven network planning solution, will be deployed nationwide.

Prior to this agreement, P.I. Works provided network planning services for Beeline, which exemplified the SmartPlan’s Return on Investment and Service Quality based planning capabilities. This initial project covered three of Russia’s branches, Moscow, Krasnodar and Novosibirsk, and optimized investments by 19% for high-level technical calculations and resulted in a reduction of 23% of the number of planned sites with LTE extensions. These results highlight the investments that Beeline Russia is making in data networks, and supports the possibility of improving time-to-market, thereby paving the way to a nationwide full-scale automated network investment planning project.

Valeriy Shorzhin, Executive VP, CTO Beeline said, “With customer experience at the forefront of everything we do, network investment planning has never been more fundamental to meeting our strategic objectives. Our aim is to achieve these while maximizing investment cost efficiencies and reducing the planning cycles. After the SmartPlan system is implemented, we intend to undertake in-depth analysis of the data coming from multiple sources in automatic mode. This gives us possibility to calculate high-level site and extension plans with high accuracy in automated mode. We expect this to create a more time-efficient investment planning process, provide more transparent calculations, and enable more structured processes given the intelligent automation capabilities of the system. We are confident that our partnership with P.I. Works will open up new opportunities for both companies.”

P.I. Works’ proprietary Smart Network Planning solution incorporates business and network metrics into a single solution to effectively forecast the network traffic volume and plan future investment decisions. It also uses inputs like Network KPIs, physical site data, point-of-interest locations, crowdsourced data, marketing data and other customer centric data to generate a priority model for investment planning decisions in line with Beeline’s planning policies.

SmartPlan solution orchestrates the investment requirements of different business units in a single platform and incorporates all layers and technologies into one process. This avoids separate planning processes for different business programs and requirements, thus eliminating redundant site investment. The solution also prioritizes the new site investments per region and technology based on Beeline’s planning policies.

Bülent Koca, Sales Director at P.I. Works said, “Teaming up with Beeline has once again proved the success of our commendable track record in network automation. We are proud to be able to cater for the needs of our partner, with the support of our unparalleled network planning offerings. We strongly believe that SmartPlan system will radically transform Beeline’s customer experience levels, all while keeping costs in check.”

About and Disclaimer
https://pi.works/2Qcjnde

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media, P.I. Works, Melih Murat, marketing@piworks.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye